4.5 Article

Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition

期刊

ACS INFECTIOUS DISEASES
卷 1, 期 4, 页码 175-184

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.5b00007

关键词

beta-Lactamase; avibactam; inhibition

资金

  1. CIHR [MT-13536]
  2. HHMI International Scholar Program
  3. CFI
  4. BCKDF
  5. Canada Research Chair Programs
  6. NSERC grant [237480]
  7. Canada Research Chair in Antibiotic Biochemistry

向作者/读者索取更多资源

Emerging beta-lactamase-mediated resistance is threatening the clinical utility of the single most prominent class of antibacterial agents used in medicine, the beta-lactams. The diazabicyclooctane avibactam is able to inhibit a wider range of serine beta-lactamases than has been previously observed with beta-lactamase inhibitors such as the widely prescribed clavulanic acid. However, despite its broad-spectrum activity, variable levels of inhibition have been observed for molecular class D beta-lactamases. In order to better understand the molecular basis and spectrum of inhibition by avibactam, we provide structural and mechanistic analysis of the compound in complex with important class A and D serine beta-lactamases. Herein, we reveal the 1.7- and 2.0-angstrom-resolution crystal structures of avibactam covalently bound to class D beta-lactamases OXA-10 and OXA-48. Furthermore, a kinetic analysis of key active-site mutants for class A beta-lactamase CTX-M-15 allows us to propose a validated mechanism for avibactam-mediated beta-lactamase inhibition including a unique role for S130, which acts as a general base. This study provides molecular insights that will aid in the design and development of avibactam-based chemotherapeutic agents effective against emerging drug-resistant microorganisms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据